# RBC-Derived, Activating Antigen Carriers (SQZ™ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo

This page is a text version of a Portal Biotechnologies publication. The bibliographic record is labeled in the text so it can be read without the surrounding website.

## Bibliographic record

- Title: RBC-Derived, Activating Antigen Carriers (SQZ™ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo
- Document type: Poster
- Year: 2021
- Outlet: SITC
- Cells: RBCs
- Cargos: Polymers, Protein, Peptide, DNA
- Page URL: https://portal.bio/publications/2021-rbc-derived-activating-antigen-carriers-sqztm-aacs-prime-potent-t-cell-responses-and--ajkGyxEAACgAc9-D
- Markdown URL: https://portal.bio/publications/2021-rbc-derived-activating-antigen-carriers-sqztm-aacs-prime-potent-t-cell-responses-and--ajkGyxEAACgAc9-D.md
- Original file: https://portal-bio.cdn.prismic.io/portal-bio/65cce1e39be9a5b998b5d1a0_SITC2021AACPosterFinal156.pdf

## Summary

Katarina Blagovic, Carolyne K. Smith, Lindsay Moore, Emrah Ilker Ozay, Armon Sharei, Howard Bernstein, Loughhead

## Publication text

The hosted file did not include text that could be read on this page.

## Provenance

Some publications reference SQZ Biotechnologies, a company Dr. Armon Sharei and colleagues previously founded. Portal is the next generation company leveraging Dr. Sharei's platform technology.